Avances terapéuticos en el tratamiento del cáncer de ovario: OLAPARIB: primer inhibidor de PARP - page 10

Study 19:

Secondary endpoints

Overall survival

Overall population

Ledermann J. et al; Lancet Oncol 2016; 17: 1579–89,

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8,9 11,12,13,14,15,16,17,18,19,20,...33